Complement Inhibition for Axonal Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for axonal regeneration in neurodegenerative diseases and injuries are limited by delayed clearance of myelin debris, which inhibits axonal growth and regeneration, and the complement system plays a significant role in this process by promoting macrophage recruitment and activation that can hinder regeneration.
Innovation Solution
The use of inhibitors of the mammalian complement system, such as complement regulators, antibodies, and small molecules, to block the formation of the membrane attack complex and inhibit both classical and alternative pathways of complement activation, facilitating axonal regeneration by reducing macrophage activation and promoting a conducive environment for nerve repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of substance
If complement system is activated to recruit macrophages for myelin clearance, then myelin debris removal is improved, but axonal regeneration is inhibited due to excessive macrophage activation and inhibitory factor release
Solution Approach 1:
The patent extracts and removes the harmful component (complement system activation) from the system while preserving the beneficial function. By administering complement inhibitors, the patent selectively blocks the complement cascade to prevent macrophage overactivation and inhibitory factor release, while still allowing controlled myelin clearance to proceed through alternative pathways.
Solution Approach 2:
The patent converts the harmful effect of complement-mediated macrophage activation into a beneficial outcome. By inhibiting the complement system, the patent prevents the release of inhibitory factors that would otherwise block axonal regeneration, thereby transforming a pathological process into a therapeutic opportunity that promotes nerve repair.
2Productivity
If macrophages are recruited to clear myelin debris, then myelin breakdown is enhanced, but the inflammatory environment becomes harmful to axonal growth
Solution Approach 1:
The patent introduces complement inhibitors as intermediary substances that mediate between myelin debris and macrophages. These inhibitors selectively block the complement cascade, preventing the transformation of myelin debris into a strongly inflammatory stimulus, thereby allowing macrophages to clear debris without releasing excessive inhibitory factors.
Solution Approach 2:
The patent changes the parameter of macrophage activation level by blocking complement system activation. This parameter change reduces the inflammatory response and inhibitory factor release while maintaining sufficient macrophage activity for myelin clearance, creating an optimal environment for axonal regeneration.
3Speed
If rapid myelin clearance is achieved through complement activation, then axonal regeneration environment is improved, but MAC deposition causes direct axonal damage
Solution Approach 1:
The patent extracts and removes the harmful terminal component (membrane attack complex) from the complement cascade by administering inhibitors that block MAC formation. This prevents direct axonal damage while allowing upstream complement activation to proceed, maintaining myelin clearance functionality without the harmful endpoint.
Solution Approach 2:
The patent applies preliminary inhibition of complement activation before MAC deposition can occur. By administering complement inhibitors early, the patent prevents the formation of harmful MAC complexes on axons while still allowing controlled myelin clearance to proceed through alternative mechanisms.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.